参芪扶正注射液联合介入治疗原发性肝癌临床研究

Clinical Study on Primary Liver Cancer Treated by Shen Qi Fu Zheng Injection Combined Interventional Therapy

目的观察参芪扶正注射液联合介入治疗发性肝癌的不良反应。方法 72例患者随机分为单纯介入治疗组(对照组)30例和参芪扶正注射液联合介入治疗组(观察组)42例,观察两组患者的不良反应发生情况。结果观察组患者白细胞减少、体温升高等不良反应发生率低于对照组,差异有统计学意义(P<0.05)。患者均有腹痛、腹胀、恶心、呕吐、乏力等表现,但观察组较轻,多数能耐受。结论参芪扶正注射液联合介入治疗,增强肝癌患者的免疫功能,减轻不良反应,提高生存质量。

Objective To observe the adverse reaction of Shen Qi Fu Zheng injection combined interventional therapy.Methods 72 patients were randomly divided into two groups： 30 cases in interventional therapy group（control group）,42 cases in Shen Qi Fu Zheng injection combined interventional therapy group（observation group）.To observe the incidence rate of adverse reaction.Results There were significant difference in the incidence rate of leucopenia and fervescence in the two groups（P0.05）.The patients had stomachache,abdominal distension,nauseated,vomiting,and acratia.but the observation group was gently,the majority coud tolerate.Conclusion Shen Qi Fu Zheng injection combined interventional therapy can strengthen the immune function of patients with liver cancer,reduce the incidence rate of adverse reaction,improve life quality.